Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
| Autor: | Emm Strijbis, Frederik Barkhof, Joep Killestein, Eme Coerver, N. F. Kalkers, Zle van Kempen, Zygj van Lierop, B Moraal, AA Toorop, Charlotte E. Teunissen, Eaj Willemse |
|---|---|
| Přispěvatelé: | Neurology, Laboratory Medicine, Amsterdam Neuroscience - Neurodegeneration, Amsterdam Neuroscience - Neuroinfection & -inflammation, Radiology and nuclear medicine, Amsterdam Neuroscience - Brain Imaging, Amsterdam Reproduction & Development (AR&D), AII - Inflammatory diseases |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Alternative therapy JC virus medicine.disease_cause progressive multifocal leukoencephalopathy Multiple sclerosis Disease activity 03 medical and health sciences Cellular and Molecular Neuroscience natalizumab 0302 clinical medicine Natalizumab ocrelizumab Internal medicine medicine 030212 general & internal medicine business.industry Brief Report Progressive multifocal leukoencephalopathy medicine.disease Relapsing remitting Ocrelizumab Neurology (clinical) business disease activity 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Multiple sclerosis journal-experimental, translational and clinical, 7(2). SAGE Publications Inc. Multiple Sclerosis Journal-Experimental, Translational and Clinical van Lierop, Z Y G J, Toorop, A A, Coerver, E M E, Willemse, E A J, Strijbis, E M M, Kalkers, N F, Moraal, B, Barkhof, F, Teunissen, C E, Killestein, J & van Kempen, Z L E 2021, ' Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients ', Multiple sclerosis journal-experimental, translational and clinical, vol. 7, no. 2 . https://doi.org/10.1177/20552173211013831 |
| ISSN: | 2055-2173 |
| DOI: | 10.1177/20552173211013831 |
| Popis: | Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|